With 795 fresh Covid-19 cases, Haryana on Friday witnessed its biggest single-day spike in 24 hours. The state’s tally stood at 24979 which included 5752 active cases.
The Covid-19 has claimed five more lives in the state. Two deaths each in Gurugram, Nuh and one in Palwal was reported in the last 24 hours taking the total toll to 327 in Haryana.
Earlier, the state had on July 14 witnessed its biggest single-day spike with 699 COVID-19 cases. In the past one week, the number of positive cases continued to surge in the state with 696 cases reported on July 16, 678 on July 15, 699 on July 14, 689 on July 13 and 648 cases on July 12.
“Out of 795 fresh cases, 160 were reported from Faridabad, 156 from Rewari, 133 from Gurugram, 69 from Sonepat, 57 from Mahendragarh, 43 from Nuh, 39 from Hisar, 26 from Panchkula, 25 from Jhajjar, 24 from Karnal among other cases.
Among critical COVID-19 patients, 59 patients are on oxygen support while 17 were on ventilator in the state,” stated Haryana Health Department’s evening bulletin.
Till date, 18,718 patients including 533 in the last 24 hours have recovered and have been discharged from hospitals in the state. With 327 COVID-19 related fatalities so far, the fatality rate is recorded at 1.32 percent in Haryana. The case-doubling rate in Haryana stood at 22 days, COVID positive rate at 5.93 per cent, recovery rate recorded at 75.48 percent, according to the health bulletin.
The bulletin stated, “The total number of cases in the worst-affected Gurugram district stood at 7483 and 112 fatalities have been reported till Friday. Faridabad has recorded 6211 cases and 104 deaths while Sonepat with 2298 cases has recorded 24 deaths.
As many as 4.24 lakh samples have been tested till date in Haryana. The report of 6268 samples is awaited, it added.
Meanwhile, Haryana Home-cum-Health Minister Anil Vij on Friday announced that clinical trials to fight COVID-19 with Covaxin have started at Post Graduate Institute of Medical Sciences, Rohtak. “Three subjects were enrolled for this purpose today (Friday). All three have tolerated the vaccine very well. There were no adverse effects,” Vij said.
Covaxin is an indigenous COVID-19 vaccine, which is being developed by Bharat Biotech and the ICMR’s National Institute of Virology, Pune. It is one of the two Indian vaccine candidates that have received the Drug Controller General of India’s nod to proceed with the phase 1 and phase 2 human clinical trials.